Scholarlink

Background <p>Research on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited. This study aimed to evaluate whether different EGFR 19del subtypes are associated with differential clinical outcomes in patients with EGFR-mutant NSCLC receiving first-line osimertinib therapy.</p> Methods <p>This study included 106 NSCLC patients with stage IIIb–IV disease from the CAPTRA-Lung database, confirmed to have EGFR 19del mutations through next-generation sequencing (NGS) and receiving first-line osimertinib. Patients were categorized based on mutation frequencies (common E746_A750del mutation or other uncommon subtypes), the deletion start codon for the EGFR 19del (E746 or L747), and the number of deleted nucleotides (15-nucleotide deletion [15n-del] or non-15n-del). Clinical characteristics, objective response rate (ORR) and progression-free survival (PFS) were compared between these subgroups.</p> Results <p>A total of 19 EGFR 19del mutation subtypes were identified. The most frequent mutation site for exon 19 deletion was E746_A750del, accounting for 56.6% of cases (<i>n</i> = 60), followed by L747_P753delinsS (9.4%, <i>n</i> = 10), L747_T751delinsP (6.6%, <i>n</i> = 7), and L747_A750delinsP (4.7%, <i>n</i> = 5). Patients in the non-15n-del group had a higher prevalence of baseline brain metastases compared with those in the 15n-del group (41.7% vs. 22.9%; <i>P</i> = 0.044). No associations were found between ORR and PFS of first-line osimertinib treatment and mutation frequencies, the deletion start codon for the EGFR 19del, and the number of deleted nucleotides. However, certain subtypes, particularly L747_A750delinsP, showed a trend toward a shorter PFS compared with the common E746_A750del subtype, although these differences did not reach statistical significance (12.3 months vs. 24.3 months; <i>P</i> = 0.100).</p> Conclusions <p>Overall, EGFR 19del subtypes showed comparable responses to first-line osimertinib. However, the trend toward poorer outcomes in the L747_A750delinsP subtype suggests potential heterogeneity that warrants confirmation in larger cohorts with longer follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月30日

查看全文
  • Dongming Zhang,
  • Yuequan Shi,
  • Xiaoyan Liu,
  • Xiaoxing Gao,
  • Minjiang Chen,
  • Jing Zhao,
  • Wei Zhong,
  • Shengjie Li,
  • Yan Xu,
  • Mengzhao Wang

摘要

Background

Research on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited. This study aimed to evaluate whether different EGFR 19del subtypes are associated with differential clinical outcomes in patients with EGFR-mutant NSCLC receiving first-line osimertinib therapy.

Methods

This study included 106 NSCLC patients with stage IIIb–IV disease from the CAPTRA-Lung database, confirmed to have EGFR 19del mutations through next-generation sequencing (NGS) and receiving first-line osimertinib. Patients were categorized based on mutation frequencies (common E746_A750del mutation or other uncommon subtypes), the deletion start codon for the EGFR 19del (E746 or L747), and the number of deleted nucleotides (15-nucleotide deletion [15n-del] or non-15n-del). Clinical characteristics, objective response rate (ORR) and progression-free survival (PFS) were compared between these subgroups.

Results

A total of 19 EGFR 19del mutation subtypes were identified. The most frequent mutation site for exon 19 deletion was E746_A750del, accounting for 56.6% of cases (n = 60), followed by L747_P753delinsS (9.4%, n = 10), L747_T751delinsP (6.6%, n = 7), and L747_A750delinsP (4.7%, n = 5). Patients in the non-15n-del group had a higher prevalence of baseline brain metastases compared with those in the 15n-del group (41.7% vs. 22.9%; P = 0.044). No associations were found between ORR and PFS of first-line osimertinib treatment and mutation frequencies, the deletion start codon for the EGFR 19del, and the number of deleted nucleotides. However, certain subtypes, particularly L747_A750delinsP, showed a trend toward a shorter PFS compared with the common E746_A750del subtype, although these differences did not reach statistical significance (12.3 months vs. 24.3 months; P = 0.100).

Conclusions

Overall, EGFR 19del subtypes showed comparable responses to first-line osimertinib. However, the trend toward poorer outcomes in the L747_A750delinsP subtype suggests potential heterogeneity that warrants confirmation in larger cohorts with longer follow-up.